Toinv

For what it's worth, this may be a "potential"  buying opportunity but not for me, I've got enough skin in this game already. Seems to me that DMs smartest decision to date was the move to a COVID therapeutic. Success as a COVID therapy IMO is RVX's last opportunity to salvage Resverlogix as an independent pharma before a Hepa takeover. COVID phII success is imperative - to paraphrase DM - our double barreled approach will be most effective against COVID - our drug has been proven safe and works - the cards are on the table - I'm all in - this is do or die waiting for the completion of another drawn out trial - an interim analysis in 2023 - right - try 2024 or 2025 - I've been holding shares since 2013 - we need to get apabetalone on the shelves now!

jmo

Chicagoest